Nature9d
Therapies for COPD
Inhaled corticosteroids (ICS), short- and long-acting β 2-agonists (SABA and LABA), long-acting muscarinic antagonists (LAMA) and fixed-dose combinations of LABA and ICS are the cornerstones of ...
Medscape16d
The Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome
With greater clinical severity, they recommend adding a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more ...
pharmaphorum11d
Boehringer's Spiolto tops Seretide in head-to-head COPD trial
which was reported at last year's ERS and showed that withdrawing the steroid component from triple therapy with LAMA/LABA/ICS had no impact on exacerbation rates in COPD. That trial was not ...
pharmaphorum6d
Novartis on point in EU for asthma triple as CHMP backs Enerzair
Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA) indacaterol, long-acting muscarinic antagonist (LAMA) glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate ...
Medscape2y
The Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome
Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.